Limits...
Biospecimen long-chain N-3 PUFA and risk of colorectal cancer: a meta-analysis of data from 60,627 individuals.

Yang B, Wang FL, Ren XL, Li D - PLoS ONE (2014)

Bottom Line: Higher biospecimen LC n-3 PUFA was significantly associated with a lower risk of CRC in case-control (pooled OR: 0.76; 95% CI: 0.59, 0.97; I2 = 10.00%) and prospective cohort studies (pooled RR: 0.70; 95% CI: 0.55, 0.88; I2 = 0.00%), respectively.A significant dose-response association was found of biospecimen C20:5n-3 (P for nonlinearity  = 0.02) and C22:6n-3 (P for trend  = 0.01) with CRC risk, respectively.Subjects without CRC have significantly higher biospecimen compositions of C20:5n-3 (SMD: 0.27; 95%: 0.13, 0.41), C22:6n-3 (SMD: 0.23; 95%: 0.11, 0.34) and total LC n-3 PUFA (SMD: 0.22; 95% CI: 0.07, 0.37) compared with those with CRC.

View Article: PubMed Central - PubMed

Affiliation: Department of Food Science and Nutrition, Zhejiang University, Hangzhou, China; Department of Preventive Medicine, Wenzhou Medical University, Wenzhou, China.

ABSTRACT

Background: Several prospective cohort and case-control studies reported the inconsistent association between biospecimen composition of C20 and C22 long-chain (LC) n-3 polyunsaturated fatty acid (PUFA) and colorectal cancer (CRC) risk. The aim of the present study was to investigate the association of biospecimen LC n-3 PUFA with CRC risk based on prospective cohort and case-control studies.

Methods and results: Cochrane Library, PubMed, and EMBASE database were searched up to February 2014 for eligible studies. Risk ratios (RRs) or odds ratios (ORs) from prospective and case-control studies were combined using a random-effects model in the highest vs. lowest categorical analysis. Nonlinear dose-response relationships were assessed using restricted cubic spline regression models. Difference in tissue composition of LC n-3 PUFA between cases and noncases was analyzed as standardized mean difference (SMD). Three prospective cohort studies and 8 case-control studies were included in the present study, comprising 60,627 participants (1,499 CRC cases and 59,128 noncases). Higher biospecimen LC n-3 PUFA was significantly associated with a lower risk of CRC in case-control (pooled OR: 0.76; 95% CI: 0.59, 0.97; I2 = 10.00%) and prospective cohort studies (pooled RR: 0.70; 95% CI: 0.55, 0.88; I2 = 0.00%), respectively. A significant dose-response association was found of biospecimen C20:5n-3 (P for nonlinearity  = 0.02) and C22:6n-3 (P for trend  = 0.01) with CRC risk, respectively. Subjects without CRC have significantly higher biospecimen compositions of C20:5n-3 (SMD: 0.27; 95%: 0.13, 0.41), C22:6n-3 (SMD: 0.23; 95%: 0.11, 0.34) and total LC n-3 PUFA (SMD: 0.22; 95% CI: 0.07, 0.37) compared with those with CRC.

Conclusions: The present evidence suggests human tissue compositions of LC n-3 PUFA may be an independent predictive factor for CRC risk, especially C20:5n-3 and C22:6n-3. This needs to be confirmed with more large-scale prospective cohort studies.

Show MeSH

Related in: MedlinePlus

Forest plot corresponding to the random-effects meta-analysis analysis on difference in biospecimen compositions of LC n-3 PUFA between cases and noncases.Case-control studies are referred to by first author, year of publication, gender and biospecimen types. The combined standardized mean difference (SMD) was achieved using random-effects model. Grey square represents SMD in each study, with square size reflecting the study-specific weight and the 95% CI represented by horizontal bars. SMD from individual study were pooled by random effect model. The diamond indicates summary SMD.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4222788&req=5

pone-0110574-g003: Forest plot corresponding to the random-effects meta-analysis analysis on difference in biospecimen compositions of LC n-3 PUFA between cases and noncases.Case-control studies are referred to by first author, year of publication, gender and biospecimen types. The combined standardized mean difference (SMD) was achieved using random-effects model. Grey square represents SMD in each study, with square size reflecting the study-specific weight and the 95% CI represented by horizontal bars. SMD from individual study were pooled by random effect model. The diamond indicates summary SMD.

Mentions: There were 4 case-control studies eligible for the analysis of different biospecimen total LC n-3 PUFA composition between cases and noncases [15]–[17], [23]. Compared with 329 cases, 457 noncases have a significantly higher LC n-3 PUFA composition in biospecimens (SMD: 0.22; 95% CI: 0.07, 0.37), with no between-study heterogeneity (I2 = 0.00%) (Figure 3). Similarly, there were 7 case-control studies eligible for analyses on different biospecimen C20:5n-3 and C22:6n-3 composition between cases and noncases [15], [17], [21]–[25], respectively. Compared with 623 CRC cases, 1315 noncases have significantly higher biospecimen C20:5n-3 (SMD: 0.27; 95% CI: 0.13, 0.41; I2 = 36.20%) and C22:6n-3 composition (SMD: 0.23; 95% CI: 0.11, 0.34; I2 = 0.00%) (Table 4). However, no significant difference was found in biospecimen C22:5n-3 composition between 587 cases and 817 noncases from 6 case-control studies (SMD: −0.08; 95% CI: −0.22, 0.06; I2 = 17.60%) (Table 4).


Biospecimen long-chain N-3 PUFA and risk of colorectal cancer: a meta-analysis of data from 60,627 individuals.

Yang B, Wang FL, Ren XL, Li D - PLoS ONE (2014)

Forest plot corresponding to the random-effects meta-analysis analysis on difference in biospecimen compositions of LC n-3 PUFA between cases and noncases.Case-control studies are referred to by first author, year of publication, gender and biospecimen types. The combined standardized mean difference (SMD) was achieved using random-effects model. Grey square represents SMD in each study, with square size reflecting the study-specific weight and the 95% CI represented by horizontal bars. SMD from individual study were pooled by random effect model. The diamond indicates summary SMD.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4222788&req=5

pone-0110574-g003: Forest plot corresponding to the random-effects meta-analysis analysis on difference in biospecimen compositions of LC n-3 PUFA between cases and noncases.Case-control studies are referred to by first author, year of publication, gender and biospecimen types. The combined standardized mean difference (SMD) was achieved using random-effects model. Grey square represents SMD in each study, with square size reflecting the study-specific weight and the 95% CI represented by horizontal bars. SMD from individual study were pooled by random effect model. The diamond indicates summary SMD.
Mentions: There were 4 case-control studies eligible for the analysis of different biospecimen total LC n-3 PUFA composition between cases and noncases [15]–[17], [23]. Compared with 329 cases, 457 noncases have a significantly higher LC n-3 PUFA composition in biospecimens (SMD: 0.22; 95% CI: 0.07, 0.37), with no between-study heterogeneity (I2 = 0.00%) (Figure 3). Similarly, there were 7 case-control studies eligible for analyses on different biospecimen C20:5n-3 and C22:6n-3 composition between cases and noncases [15], [17], [21]–[25], respectively. Compared with 623 CRC cases, 1315 noncases have significantly higher biospecimen C20:5n-3 (SMD: 0.27; 95% CI: 0.13, 0.41; I2 = 36.20%) and C22:6n-3 composition (SMD: 0.23; 95% CI: 0.11, 0.34; I2 = 0.00%) (Table 4). However, no significant difference was found in biospecimen C22:5n-3 composition between 587 cases and 817 noncases from 6 case-control studies (SMD: −0.08; 95% CI: −0.22, 0.06; I2 = 17.60%) (Table 4).

Bottom Line: Higher biospecimen LC n-3 PUFA was significantly associated with a lower risk of CRC in case-control (pooled OR: 0.76; 95% CI: 0.59, 0.97; I2 = 10.00%) and prospective cohort studies (pooled RR: 0.70; 95% CI: 0.55, 0.88; I2 = 0.00%), respectively.A significant dose-response association was found of biospecimen C20:5n-3 (P for nonlinearity  = 0.02) and C22:6n-3 (P for trend  = 0.01) with CRC risk, respectively.Subjects without CRC have significantly higher biospecimen compositions of C20:5n-3 (SMD: 0.27; 95%: 0.13, 0.41), C22:6n-3 (SMD: 0.23; 95%: 0.11, 0.34) and total LC n-3 PUFA (SMD: 0.22; 95% CI: 0.07, 0.37) compared with those with CRC.

View Article: PubMed Central - PubMed

Affiliation: Department of Food Science and Nutrition, Zhejiang University, Hangzhou, China; Department of Preventive Medicine, Wenzhou Medical University, Wenzhou, China.

ABSTRACT

Background: Several prospective cohort and case-control studies reported the inconsistent association between biospecimen composition of C20 and C22 long-chain (LC) n-3 polyunsaturated fatty acid (PUFA) and colorectal cancer (CRC) risk. The aim of the present study was to investigate the association of biospecimen LC n-3 PUFA with CRC risk based on prospective cohort and case-control studies.

Methods and results: Cochrane Library, PubMed, and EMBASE database were searched up to February 2014 for eligible studies. Risk ratios (RRs) or odds ratios (ORs) from prospective and case-control studies were combined using a random-effects model in the highest vs. lowest categorical analysis. Nonlinear dose-response relationships were assessed using restricted cubic spline regression models. Difference in tissue composition of LC n-3 PUFA between cases and noncases was analyzed as standardized mean difference (SMD). Three prospective cohort studies and 8 case-control studies were included in the present study, comprising 60,627 participants (1,499 CRC cases and 59,128 noncases). Higher biospecimen LC n-3 PUFA was significantly associated with a lower risk of CRC in case-control (pooled OR: 0.76; 95% CI: 0.59, 0.97; I2 = 10.00%) and prospective cohort studies (pooled RR: 0.70; 95% CI: 0.55, 0.88; I2 = 0.00%), respectively. A significant dose-response association was found of biospecimen C20:5n-3 (P for nonlinearity  = 0.02) and C22:6n-3 (P for trend  = 0.01) with CRC risk, respectively. Subjects without CRC have significantly higher biospecimen compositions of C20:5n-3 (SMD: 0.27; 95%: 0.13, 0.41), C22:6n-3 (SMD: 0.23; 95%: 0.11, 0.34) and total LC n-3 PUFA (SMD: 0.22; 95% CI: 0.07, 0.37) compared with those with CRC.

Conclusions: The present evidence suggests human tissue compositions of LC n-3 PUFA may be an independent predictive factor for CRC risk, especially C20:5n-3 and C22:6n-3. This needs to be confirmed with more large-scale prospective cohort studies.

Show MeSH
Related in: MedlinePlus